Clinical trials: Medium Vessel Occlusion
Atherosclerosis
Women's Isoflavone Soy Health (WISH) Trial
The purpose of this study is to determine whether soy supplementation can reduce hardening of the arteries and cognitive decline in postmenopausal women.
- Trial name
- NCT00118846
- Testing
- 25 gm soy protein supplement
- Where
- United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Carotid Atherosclerosis, Carotid Intimal Medial Thickness 1
Effects of Lutein Supplementation on Subclinical Atherosclerosis
This study is to investigate the possible positive effects of lutein and lycopene supplementation on early atherosclerosis in Beijing.
- Trial name
- NCT01534533
- Testing
- Lutein group, Combination group, Normal lutein control group
- Where
- China
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Peking University
Atherosclerosis
ELITE: Early Versus Late Intervention Trial With Estradiol
The purpose of this study is to examine the effects of oral 17B-estradiol (estrogen) on the progression of early (subclinical) atherosclerosis and cognitive decline in healthy postmenopausal women.
- Trial name
- NCT00114517
- Testing
- 17B-estradiol
- Where
- United States
- Volunteers
- 643 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Coronary Artery Disease
Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography
The aim of this study is to determine how two different types of iodinated contrast media (CM) agents, low-osmolar ionic ioxaglate and iso-osmolar non-ionic iodixanol, affect specific markers of thrombogenesis and platelet…
- Trial name
- NCT01848899
- Testing
- Iodixanol, Ioxaglate, Bivalirudin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- NYU Langone Health
Atherosclerosis
A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis
The purpose of this study is to evaluate the effects of of rosuvastatin 20 mg compared to placebo for treating Chinese patients with subclinical atherosclerosis.
- Trial name
- NCT02546323
- Testing
- Rosuvastatin
- Where
- 24 sites in China
- Volunteers
- 543 people
- Sponsor
- AstraZeneca
Prevention of Subclinical Atherosclerosis Progression, Prevention of Cognitive Decline
Nattokinase Atherothrombotic Prevention Study
The potential for nattokinase to "thin" blood and to reduce blood clotting by positive antithrombotic and fibrinolytic effects presents a unique opportunity to safely study such effects on cardiovascular disease and cognition.
- Trial name
- NAPS (NCT02080520)
- Testing
- Nattokinase
- Where
- United States
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Coronary Artery Disease, Coronary Heart Disease
Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood
The primary purpose of this study is to test the effect and safety of once daily ABT-335 on the thickness of the lining of the carotid artery (a blood vessel to the brain) in patients with abnormal blood lipids who have optimal…
- Conditions
- Coronary Artery Disease, Coronary Heart Disease, Dyslipidemia
- Trial name
- FIRST (NCT00616772)
- Testing
- ABT-335, Atorvastatin
- Where
- 124 sites in United States
- Volunteers
- 682 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Coronary Artery Disease
Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography
The purpose of this study is to demonstrate the (statistical) non-inferiority of iobitridol (Xenetix® 350) when compared to contrast agents with higher iodine concentrations, iopromide (Ultravist® 370) and iomeprol (Iomeron® 400)…
- Trial name
- X-ACT (NCT01255722)
- Testing
- iobitridol, iopromide, iomeprol
- Where
- 23 sites in France, Germany and 3 more
- Volunteers
- 468 people
- Sponsor
- Guerbet